Bio News
Amgen said its Sjögren syndrome drug candidate dazodalibep met the primary endpoint in the first of two phase 3 trials.
Amgen reported statistically significant and clinically meaningful improvement in a disease activity measure at week 48, with effects emerging as early as week 4 of treatment and maintained throughout the assessment period.
Amgen added that no imbalance was observed in the incidence of thrombosis or opportunistic infections, and that adverse events were generally mild to moderate.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
